Literature DB >> 18488218

Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Lazar Vujanovic1, Theresa L Whiteside, Douglas M Potter, Jessica Chu, Soldano Ferrone, Lisa H Butterfield.   

Abstract

Recombinant adenoviral vectors (AdV) are potent vehicles for antigen engineering of dendritic cells (DC). DC engineered with AdV to express full length tumor antigens are capable stimulators of antigen-specific polyclonal CD8+ and CD4+ T cells. To determine the impact of AdV on the HLA class I antigen presentation pathway, we investigated the effects of AdV transduction on antigen processing machinery (APM) components in human DC. Interactions among AdV transduction, maturation, APM regulation and T cell activation were investigated. The phenotype and cytokine profile of DC transduced with AdV was intermediate, between immature (iDC) and matured DC (mDC). Statistically significant increases in expression were observed for peptide transporters TAP-1 and TAP-2, and HLA class I peptide-loading chaperone ERp57, as well as co-stimulatory surface molecule CD86 due to AdV transduction. AdV transduction enhanced the expression of APM components and surface markers on mDC, and these changes were further modulated by the timing of DC maturation. Engineering of matured DC to express a tumor-associated antigen stimulated a broader repertoire of CD8+ T cells, capable of recognizing immunodominant and subdominant epitopes. These data identify molecular changes in AdV-transduced DC (AdV/DC) that could influence T cell priming and should be considered in design of cancer vaccines.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18488218      PMCID: PMC2726804          DOI: 10.1007/s00262-008-0533-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  54 in total

1.  A mechanism underlying synergy between IL-12 and IFN-gamma-inducing factor in enhanced production of IFN-gamma.

Authors:  H J Ahn; S Maruo; M Tomura; J Mu; T Hamaoka; K Nakanishi; S Clark; M Kurimoto; H Okamura; H Fujiwara
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

2.  Langerhans cells derived from genetically modified human CD34+ hemopoietic progenitors are more potent than peptide-pulsed Langerhans cells for inducing antigen-specific CD8+ cytolytic T lymphocyte responses.

Authors:  Jianda Yuan; Jean-Baptiste Latouche; John L Reagan; Glenn Heller; Isabelle Riviere; Michel Sadelain; James W Young
Journal:  J Immunol       Date:  2005-01-15       Impact factor: 5.422

3.  A comparison of gene transfer methods in human dendritic cells.

Authors:  J F Arthur; L H Butterfield; M D Roth; L A Bui; S M Kiertscher; R Lau; S Dubinett; J Glaspy; W H McBride; J S Economou
Journal:  Cancer Gene Ther       Date:  1997 Jan-Feb       Impact factor: 5.987

4.  T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.

Authors:  M A Lowes; G A Bishop; K Crotty; R S Barnetson; G M Halliday
Journal:  J Invest Dermatol       Date:  1997-06       Impact factor: 8.551

5.  Human PBMC-derived dendritic cells transduced with an adenovirus vectorinduce cytotoxic T-lymphocyte responses against a vector-encoded antigen in vitro.

Authors:  J Diao; J A Smythe; C Smyth; P B Rowe; I E Alexander
Journal:  Gene Ther       Date:  1999-05       Impact factor: 5.250

6.  Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein.

Authors:  L H Butterfield; A Koh; W Meng; C M Vollmer; A Ribas; V Dissette; E Lee; J A Glaspy; W H McBride; J S Economou
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

7.  Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7.

Authors:  M Gaczynska; A L Goldberg; K Tanaka; K B Hendil; K L Rock
Journal:  J Biol Chem       Date:  1996-07-19       Impact factor: 5.157

8.  Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.

Authors:  L H Butterfield; S M Jilani; N G Chakraborty; L A Bui; A Ribas; V B Dissette; R Lau; S C Gamradt; J A Glaspy; W H McBride; B Mukherji; J S Economou
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

9.  B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.

Authors:  P E Fields; R J Finch; G S Gray; R Zollner; J L Thomas; K Sturmhoefel; K Lee; S Wolf; T F Gajewski; F W Fitch
Journal:  J Immunol       Date:  1998-11-15       Impact factor: 5.422

10.  Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7.

Authors:  M Gaczynska; K L Rock; T Spies; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

View more
  19 in total

1.  Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Authors:  Lazar Vujanovic; David E Szymkowski; Sean Alber; Simon C Watkins; Nikola L Vujanovic; Lisa H Butterfield
Journal:  Blood       Date:  2010-04-29       Impact factor: 22.113

2.  Molecular mimicry of MAGE-A6 and Mycoplasma penetrans HF-2 epitopes in the induction of antitumor CD8+ T-cell responses.

Authors:  Lazar Vujanovic; Jian Shi; John M Kirkwood; Walter J Storkus; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2014-11-14       Impact factor: 8.110

Review 3.  New approaches to the development of adenoviral dendritic cell vaccines in melanoma.

Authors:  Lisa H Butterfield; Lazar Vujanovic
Journal:  Curr Opin Investig Drugs       Date:  2010-12

4.  Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Authors:  Takuya Osada; Christopher Y Woo; Matthew McKinney; Xiao Yi Yang; Gangjun Lei; Heather G Labreche; Zachary C Hartman; Donna Niedzwiecki; Nelson Chao; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

5.  Viral IL-10 down-regulates the "MHC-I antigen processing operon" through the NF-κB signaling pathway in nasopharyngeal carcinoma cells.

Authors:  Yan-Xin Ren; Jie Yang; Rui-Mei Sun; Li-Juan Zhang; Liu-Fang Zhao; Bao-Zhong Li; Lei Li; Hai-Ting Long; Qiang-Ming Sun; Yun-Chao Huang; Xiao-Jiang Li
Journal:  Cytotechnology       Date:  2016-09-20       Impact factor: 2.058

Review 6.  Strategies to overcome host immunity to adenovirus vectors in vaccine development.

Authors:  Erin E Thacker; Laura Timares; Qiana L Matthews
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

Review 7.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

8.  Adenovirus expressing β2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition.

Authors:  A B Del Campo; J Carretero; J A Muñoz; S Zinchenko; F Ruiz-Cabello; G González-Aseguinolaza; F Garrido; N Aptsiauri
Journal:  Cancer Gene Ther       Date:  2014-06-27       Impact factor: 5.987

9.  Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients.

Authors:  Yan-Xin Ren; Jie Yang; Li-Juan Zhang; Rui-Mei Sun; Liu-Fang Zhao; Ming Zhang; Yun Chen; Jing Ma; Kun Qiao; Qiang-Ming Sun; Hai-Ting Long; Yun-Chao Huang; Xiao-Jiang Li
Journal:  Mol Clin Oncol       Date:  2013-09-26

10.  Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1.

Authors:  Ryo Ueda; Gary Kohanbash; Kotaro Sasaki; Mitsugu Fujita; Xinmei Zhu; Edward R Kastenhuber; Heather A McDonald; Douglas M Potter; Ronald L Hamilton; Michael T Lotze; Saleem A Khan; Robert W Sobol; Hideho Okada
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.